Inflammatory Regulation Effect of NAC on COVID-19 Treatment

Dr. Tariq Alhawassi1,180 enrolled

Overview

Study times to evaluate the efficacy of N-Acetylcysteine therapy in the management of adult admitted patients with COVID-19.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

1,180

Conditions

COVID-19

Interventions

N-Acetyl cysteineDRUG

150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)

PlaceboDRUG

Matching placebo administered in the same schedule and volume as NAC

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult above 18 years of age * Admitted to the hospital With confirmed COVID-19 by RT-PCR test * On oxygen supplement Exclusion Criteria: * Active use of NAC * Known NAC allergy * In the opinion of the treating team, progression of death is imminent and inevitable within the next 24 hour, irrespective of provision treatment * All patients enrolled in any other investigational drug studies in COVID-19.

Outcomes

Primary Outcomes

Time to Recovery

Day of recovery is defined as the first day on which of the following three categories from The Ordinal Scale on Covid-19 Clinical Improvement 1. Not-Hospitalized, No limitation on activity. 2. Not Hospitalized, with limitation on activity. 3. Hospitalized, Not requiring supplemental Oxygen

Time frame: 28 days

Central Contacts

Baian Alabdulbaqi, MD

CONTACT

+966114670011 balabdulbaqi@ksu.edu.sa

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.